SciSight Ecosystem
WoS SCIE Q1Scopus Q1SCImago #413CAS 1区Top JournalGold OA

Experimental Hematology & Oncology

Abbreviation (ISO):EXP. HEMATOL. ONCOL
Country: England•WoS SCIE Quartile: Q1•Scopus SJR: 4.126•SCImago Rank: #413•Identifier (ISSN):2162-3619(Print)•Articles / Year: 44•Estimated Publication Fee (APC): $3,960 USD
Clarivate IF (2026)Q1
17.5
↑ +4

Leading citation impact metric from Clarivate Journal Citation Reports

JCR Release Date: 2026-06-17
H-Index (Hirsch Index)
58

58 papers with at least that number of citations each

WoS: SCIE / JCRTop Tier
Self-Citation Rate6.4%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessGold OA
44articles/year
100% Gold OA•50% Original Research

State Council for Professorship (HĐGSNN) Scoring

Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)

3.00pts
Latest Max Score
Estimated (Dec 26)
Scoring Basis: WoS Q1 có IF ≥ 5.0(IF: 17.5)

HĐGSNN Score History

By article publication year
YearMax ScoreEvaluation DetailsSource
20263.00đ
WoS Q1 có IF ≥ 5.0(IF: 17.5)
🔵 Computed
20253.00đ
WoS Q1 có IF ≥ 5.0(IF: 13.5)
🔵 Computed
20243.00đ
WoS Q1 có IF ≥ 5.0(IF: 9.4)
🔵 Computed
20233.00đ
WoS Q1 có IF ≥ 5.0(IF: 10.9)
🔵 Computed
20223.00đ
WoS Q1 có IF ≥ 5.0(IF: 8.593)
🔵 Computed
20213.00đ
WoS Q1 có IF ≥ 5.0(IF: 5.133)
🔵 Computed
20202.50đ
WoS Q1 có IF ≥ 3.0(IF: 3.492)
🔵 Computed

Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.

Aims & Scope

Experimental Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology with emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with "negative" or preliminary results and basic science studies with provocative findings.

Topics Covered (Recognized by AI)
Biology99.8%Medicine99.1%Internal medicine96.7%Genetics95%Immunology78.1%Chemistry69.8%Biochemistry65.2%Pathology63%Cancer research58%Cancer46.2%Oncology41.8%Gene41.4%Surgery41.1%Cell biology38.3%Psychology37.6%Psychiatry36.3%Hematology28.9%Immune system25.2%Chemotherapy20.6%
Primary Research Areas

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #413Scopus Q1SCImago Profile
Scopus Coverage:2012-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicine
Scopus Citation Rank (SJR)Q1
4.126

Weighted prestige citation metric per document indexed in the Scopus database.

Tứ phân vị: Scopus Q1
Scopus H-Index (2025)
58

Measures cumulative publication volume and citation impact.

Scopus Database Indexed (2025)
Citations / Doc (2 years)
10.49

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,960 USD

Estimated Article Processing Charge for Open Access publication.

Chi phí ước tính / bài báo

Scopus 3-Year Publication & Citation Window

3-Year Citations3,240
3-Year Documents325
Citable Documents210

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate43.8%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Cancer ResearchQ1
HematologyQ1
OncologyQ1

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
1区 (Zone 1)Medicine
Minor Category (Specific Field):
1区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Publisher Review Speed
Updating
Average time to first editorial decision
Online Publication Speed
Updating
Time from acceptance to online publication
Official Acceptance Rate
Updating
Manuscript acceptance rate confirmed by the publisher
Open Access Model
Gold OA
OA publishing option or traditional subscription
Publisher
BioMed Central
Publication Language
English
Frequency
Periodic
Founding Year
2012
Editorial Address
CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW
Indexing & Databases
SCIEScopusDOAJPubMed

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
CategoryIndexRankQuartile
HEMATOLOGY
JCRSCIE
5/103Q1
ONCOLOGY
JCRSCIE
19/333Q1
HEMATOLOGY
JCISCIE
6/103Q1
ONCOLOGY
JCISCIE
28/333Q1

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
YearImpact FactorArticles / YearTotal Citations
2026—98108
202513.51411,979
20249.41232,856
202310.91053,610
20228.5931083,864
20215.133602,780
20203.492373,052
2019—32956
2018—321,309
2017—321,123
2016—117
2015—641,771
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Impact Factor Trend (2018–2024)

Clarivate IF trend for Experimental Hematology & Oncology

WoS Q1
27111620202021202220232024202513.50
Annual Impact Factor Metric
2025:13.5

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 6.4%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 019f6d18-49fc-4e3d-ac5d-51819fd88d7d
Database Updated: 2026-10-01